{"id":4128,"date":"2026-11-05T09:00:00","date_gmt":"2026-11-05T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4128"},"modified":"2026-11-07T16:07:51","modified_gmt":"2026-11-07T20:07:51","slug":"china-approves-im19-car-t-for-later-line-large-b-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4128","title":{"rendered":"China Approves IM19 CAR T for Later-Line Large B Cell Lymphoma"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4142\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Imunopharm_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Beijing Imunopharm<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>NMPA approval (China)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous CD19 CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Poji-ocel (IM19, Saibohua)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Relapsed or refractory large B-cell lymphoma<\/p>\n<h4>Summary<\/h4>\n<p>Previously missed November 5 event, confirmed by a company announcement and the regulator-linked Chinese announcement on November 6: China approved poji-ocel (IM19, Saibohua), an autologous CD19 CAR T therapy, for adults with relapsed or refractory large B-cell lymphoma after at least two systemic lines. Approval is domestic; no US or European authorization follows from it.<\/p>\n<p>The labeled population includes DLBCL not otherwise specified, grade 3b follicular lymphoma and high-grade B-cell lymphoma. A company-reported single-arm Phase 2 study included 101 infused patients and reported three-month objective response of 58.3% and best response of 72.9%; these are different endpoints. The original Chinese company notice was November 5, preceding November 6 English-language radar.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> another domestic CD19 CAR T may widen treatment access and create local manufacturing competition. Approval and a 101-person infused dataset support this, but capacity, price and reimbursement are not established.<\/p>\n<p><strong>Interpretation B:<\/strong> the entry may have limited displacement because established CAR T products and bispecifics already compete, while cross-trial response comparisons are unreliable. Durability, grade 3 or higher CRS and ICANS, vein-to-vein time, failure rate, survival and real-world access will discriminate. Regulatory portability requires independent CMC and pivotal-study assessment.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Beijing Imunopharm develops IM19. Patient T cells are collected, engineered ex vivo to recognize CD19 on malignant B cells, expanded and infused after lymphodepletion.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>The approval itself is corroborated; the comparative toxicity and persistence advantages are company claims.<\/li>\n<li>No randomized comparator was disclosed.<\/li>\n<li>This is a China-specific regulatory and commercial signal, with global relevance for CAR T manufacturing competition.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A material China hematology approval; the evidence supports market entry, not superiority to existing products.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive for regulatory status; uncertain for comparative benefit. Confidence in Facts: high for approval, moderate for sponsor-reported trial metrics. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Previously missed November 5 event, confirmed by a company announcement and the regulator-linked Chinese announcement on November 6: China approved poji-ocel (IM19, Saibohua), an autologous CD19 CAR T therapy, for adults with relapsed or&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4142,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1401,1400,130],"class_list":["post-4128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-im19","tag-imunopharm","tag-large-b-cell-lymphoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4128"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4128\/revisions"}],"predecessor-version":[{"id":4150,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4128\/revisions\/4150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4142"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}